Samsung C&T (028260) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
10 Mar, 2026Executive summary
Achieved consolidated sales of KRW 9,737 bn in 1Q25, down 9.8% year-over-year and 2.6% sequentially, with net profit of KRW 937 bn, up 14% year-over-year and 43% sequentially.
Operating profit rose to KRW 724 bn, up 1.7% year-over-year and 14% sequentially, with an improved operating margin of 7.4%.
Growth in Bio and T&I segments offset declines in E&C, Fashion, and Leisure.
Financial highlights
Gross profit increased to KRW 1,753 bn, up 6.3% year-over-year.
Non-operating profit surged to KRW 436 bn, up KRW 299 bn sequentially.
Net cash position at KRW 992 bn, down from KRW 1,262 bn at end of 2024.
Total assets at KRW 62,458 bn, equity at KRW 38,334 bn.
Outlook and guidance
Targeting 22GW solar pipeline and $100 million in asset disposal gains in 2025 for T&I.
Continued focus on landmark housing projects and SMR (Small Modular Reactor) expansion in Europe.
Bio segment expects further growth with Plant 5 operations and large CMO contracts.
Latest events from Samsung C&T
- 2Q24 delivered robust profit growth, led by Bio and F&B, amid ongoing business diversification.028260
Q2 202410 Mar 2026 - 3Q24 profit declined year-over-year, but F&B and bio segments showed strong growth.028260
Q3 202410 Mar 2026 - Net profit rose 15% year-over-year in 4Q 2024, driven by Bio and T&I growth.028260
Q4 202410 Mar 2026 - Sequential sales and operating profit rose, but net profit fell; Bio outlook upgraded.028260
Q2 202510 Mar 2026 - Operating profit and net profit surged YoY, driven by Bio and F&B, with robust new orders.028260
Q3 202510 Mar 2026 - Net profit surged YoY in 4Q25, with Bio and E&C driving growth and a positive 2026 outlook.028260
Q4 202510 Mar 2026